Literature DB >> 18334293

Pyrimidine-based inhibitors of CaMKIIdelta.

Babu Mavunkel1, Yong-Jin Xu, Bindu Goyal, Don Lim, Qing Lu, Zheng Chen, Dan-Xiong Wang, Jeffrey Higaki, Indrani Chakraborty, Albert Liclican, Steve Sideris, Maureen Laney, Ulrike Delling, Rosanne Catalano, Linda S Higgins, Hui Wang, Jing Wang, Ying Feng, Sundeep Dugar, Daniel E Levy.   

Abstract

Non-ATP competitive pyrimidine-based inhibitors of CaMKIIdelta were identified. Computational studies were enlisted to predict the probable mode of binding. The results of the computational studies led to the design of ATP competitive inhibitors with optimized hinge interactions. Inhibitors of this class possessed improved enzyme and cellular activity compared to early leads.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334293     DOI: 10.1016/j.bmcl.2008.02.056

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  One-pot Double Suzuki Couplings of Dichloropyrimidines.

Authors:  Samantha C Anderson; Scott T Handy
Journal:  Synthesis (Stuttg)       Date:  2010-08-01       Impact factor: 3.157

2.  Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor.

Authors:  Stefan Neef; Alexander Steffens; Patricia Pellicena; Julian Mustroph; Simon Lebek; Katharina R Ort; Howard Schulman; Lars S Maier
Journal:  J Mol Cell Cardiol       Date:  2017-12-30       Impact factor: 5.000

Review 3.  CaMKII inhibitors: from research tools to therapeutic agents.

Authors:  Patricia Pellicena; Howard Schulman
Journal:  Front Pharmacol       Date:  2014-02-20       Impact factor: 5.810

Review 4.  Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.

Authors:  Rand Shahin; Omar Shaheen; Faris El-Dahiyat; Maha Habash; Sana Saffour
Journal:  Future Sci OA       Date:  2017-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.